Vanda Pharmaceuticals Inc.VNDAEarnings & Financial Report
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
Revenue
$56.3M
Gross Profit
N/A
Operating Profit
$-31.3M
Net Profit
$-22.6M
Gross Margin
N/A
Operating Margin
-55.6%
Net Margin
-40.1%
YoY Growth
18.1%
EPS
$-0.38
Vanda Pharmaceuticals Inc. Q3 FY2025 Financial Summary
Vanda Pharmaceuticals Inc. reported revenue of $56.3M (up 18.1% YoY) for Q3 FY2025, with a net profit of $-22.6M (down 324.2% YoY) (-40.1% margin).
Key Financial Metrics
| Total Revenue | $56.3M |
|---|---|
| Net Profit | $-22.6M |
| Gross Margin | N/A |
| Operating Margin | -55.6% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
Vanda Pharmaceuticals Inc. Q3 FY2025 revenue of $56.3M breaks down across 3 segments, led by Fanapt at $31.2M (55.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Fanapt | $31.2M | 55.5% |
| Hetlioz | $18.0M | 32.0% |
| PONVORY | $7.0M | 12.5% |
Vanda Pharmaceuticals Inc. Revenue by Segment — Quarterly Trend
Vanda Pharmaceuticals Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Fanapt and Hetlioz) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Fanapt | $33.2M | $31.2M | $29.3M | $23.5M |
| Hetlioz | $16.4M | $18.0M | $16.2M | $20.9M |
| PONVORY | $7.6M | $7.0M | $7.1M | $5.6M |
Vanda Pharmaceuticals Inc. Annual Revenue by Year
Vanda Pharmaceuticals Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $216.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $216.1M |
| 2024 | $198.8M |
| 2023 | $192.6M |
| 2022 | $254.4M |
Vanda Pharmaceuticals Inc. Quarterly Revenue & Net Profit History
Vanda Pharmaceuticals Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $57.2M | +7.6% | $-141.2M | -246.8% |
| Q3 FY2025 | $56.3M | +18.1% | $-22.6M | -40.1% |
| Q2 FY2025 | $52.6M | +4.2% | $-27.2M | -51.7% |
| Q1 FY2025 | $50.0M | +5.4% | $-29.5M | -58.9% |
| Q4 FY2024 | $53.2M | +17.5% | $-4.9M | -9.2% |
| Q3 FY2024 | $47.7M | +22.8% | $-5.3M | -11.2% |
| Q2 FY2024 | $50.5M | +9.6% | $-4.5M | -9.0% |
| Q1 FY2024 | $47.5M | -24.1% | $-4.1M | -8.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.5M | $50.5M | $47.7M | $53.2M | $50.0M | $52.6M | $56.3M | $57.2M |
| YoY Growth | -24.1% | 9.6% | 22.8% | 17.5% | 5.4% | 4.2% | 18.1% | 7.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $652.7M | $651.4M | $645.1M | $656.2M | $631.9M | $624.7M | $601.1M | $488.9M |
| Liabilities | $108.7M | $108.9M | $103.9M | $117.7M | $120.5M | $138.4M | $135.1M | $161.8M |
| Equity | $544.0M | $542.5M | $541.2M | $538.5M | $511.4M | $486.3M | $466.0M | $327.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $7.6M | $-6.9M | $-14.6M | $-1.8M | $-33.1M | $-15.3M | $-31.6M | $-29.4M |